Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Viking Therapeutics ( VKTX -2.05%) didn't exactly capture investors' hearts in the final month of 2024. The biotech company's ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

Viking Therapeutics (VKTX) has received a new Buy rating, initiated by Stifel Nicolaus analyst, Annabel Samimy.Stay Ahead of the ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Seeking Alpha analyst Terry Chrisomalis regards Viking Therapeutics as the most attractive M&A candidate in 2025, bolstered ...

It's been an excellent year for Viking Therapeutics ( VKTX 4.30%), a mid-cap biotech company. Thanks to impressive mid-stage ...

NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors ...

Let's find out. Viking Therapeutics' leading candidate, VK2735, is a potential GLP-1 weight loss medicine. It reported excellent results in a phase 2 study. The company also has an oral ...